Summary of COVID-19 icatibant studies
Hide extended summaries
RCT 77 hospitalized COVID-19 pneumonia patients requiring supplemental oxygen, showing reduced oxygen requirements, hospital stay, and mortality with icatibant treatment compared to standard care alone.
Jan 2023, Clinical Infectious Diseases, https://academic.oup.com/cid/article/76/10/1784/6969085, https://c19p.org/malchair
RCT 30 severe COVID-19 patients showing no significant difference in mortality or hospitalization time with kinin-kallikrein system inhibitors icatibant or iC1e/K. While there was no impact on mortality or hospitalization time, both treatments were safe and showed improvements in lung CT scores and increased blood eosinophil counts.
Feb 2021, Viruses, https://www.mdpi.com/1999-4915/13/2/309, https://c19p.org/mansour3icat
RCT severe COVID-19 patients showing no significant difference in outcomes with icatibant.
Mar 2023, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537023000664, https://c19p.org/filesicat
1. Malchair et al., Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial
73 patient icatibant late treatment RCT: 47% lower mortality (p=0.01), 46% higher hospital discharge (p=0.01), and 41% lower need for oxygen therapy (p=0.03).RCT 77 hospitalized COVID-19 pneumonia patients requiring supplemental oxygen, showing reduced oxygen requirements, hospital stay, and mortality with icatibant treatment compared to standard care alone.
Jan 2023, Clinical Infectious Diseases, https://academic.oup.com/cid/article/76/10/1784/6969085, https://c19p.org/malchair
2. Mansour et al., Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19
20 patient icatibant late treatment RCT: 67% lower mortality (p=1) and 5% lower hospital discharge (p=0.89).RCT 30 severe COVID-19 patients showing no significant difference in mortality or hospitalization time with kinin-kallikrein system inhibitors icatibant or iC1e/K. While there was no impact on mortality or hospitalization time, both treatments were safe and showed improvements in lung CT scores and increased blood eosinophil counts.
Feb 2021, Viruses, https://www.mdpi.com/1999-4915/13/2/309, https://c19p.org/mansour3icat
3. Files et al., Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
279 patient icatibant late treatment RCT: 6% higher mortality (p=0.79) and 18% worse recovery (p=0.35).RCT severe COVID-19 patients showing no significant difference in outcomes with icatibant.
Mar 2023, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537023000664, https://c19p.org/filesicat
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.